Brokers Offer Predictions for Opus Genetics FY2030 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at Brookline Capital Markets issued their FY2030 earnings per share (EPS) estimates for Opus Genetics in a research report issued on Monday, August 10th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings per share of $0.62 for the year. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.09) per share.

IRD has been the subject of a number of other research reports. Citigroup initiated coverage on shares of Opus Genetics in a research report on Tuesday, April 28th. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Opus Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Chardan Capital restated a “buy” rating and set a $13.00 price objective on shares of Opus Genetics in a research report on Monday, July 6th. BTIG Research reaffirmed a “buy” rating and issued a $12.00 target price on shares of Opus Genetics in a research note on Monday, July 6th. Finally, Royal Bank Of Canada dropped their price target on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.69.

Opus Genetics Trading Up 6.0%

Shares of NASDAQ IRD opened at $3.88 on Wednesday. The stock has a market cap of $320.68 million, a price-to-earnings ratio of -2.87 and a beta of 0.59. Opus Genetics has a 52 week low of $1.04 and a 52 week high of $5.81. The company’s 50-day moving average price is $3.80 and its 200 day moving average price is $4.14.

Opus Genetics (NASDAQ:IRD) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $2.63 million.

Institutional Trading of Opus Genetics

Several institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC increased its holdings in shares of Opus Genetics by 42.9% during the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after buying an additional 1,435,407 shares during the last quarter. BlackRock Inc. acquired a new position in Opus Genetics in the second quarter valued at $12,809,000. Balyasny Asset Management L.P. acquired a new position in Opus Genetics in the fourth quarter valued at $5,463,000. Millennium Management LLC purchased a new stake in Opus Genetics during the fourth quarter valued at about $4,025,000. Finally, ADAR1 Capital Management LLC grew its position in Opus Genetics by 4,522.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock valued at $8,413,000 after acquiring an additional 1,809,004 shares during the period. 14.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO George Magrath sold 9,475 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the completion of the sale, the chief executive officer directly owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the transaction, the director directly owned 3,792,171 shares of the company’s stock, valued at $16,495,943.85. This trade represents a 30.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 1,729,331 shares of company stock valued at $7,481,629. 11.70% of the stock is owned by insiders.

Key Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts, improving its projected Q4 2026 EPS to a loss of $0.09 from a loss of $0.14 and its FY2026 estimate to a loss of $1.03 from a loss of $1.18. The firm also raised its FY2027 forecast to a loss of $0.40 from a loss of $0.46.
• Positive Sentiment: Analysts project a potential transition to profitability. HC Wainwright forecasts positive EPS of $0.05 in FY2029 and $0.27 in FY2030, while Brookline Capital Markets expects significantly higher FY2030 EPS of $0.62. These longer-term estimates may support investor optimism about Opus Genetics’ pipeline and commercial prospects.
• Positive Sentiment: HC Wainwright maintained a Buy rating and an $8.00 price target. Against the stock’s recent opening price of $3.88, the target implies substantial potential upside, although it depends on the company meeting distant earnings projections.
• Neutral Sentiment: Short-interest data provided no meaningful signal. Reported short interest was zero shares as of August 11, matching the prior period, with a zero-day short-interest ratio. However, the reported percentage change was listed as “NaN,” indicating unreliable or incomplete data.
• Negative Sentiment: Opus Genetics is still expected to report substantial losses in the near term. HC Wainwright estimates EPS of negative $1.03 for FY2026 and negative $0.16 for FY2028, while the broader consensus remains at negative $1.09 for the current fiscal year. The company also has a history of heavy losses and limited revenue, increasing execution and financing risks.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.